Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1107, USA.
Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892-1107, USA.
Cancer Cell. 2016 Oct 10;30(4):515-517. doi: 10.1016/j.ccell.2016.09.016.
In two recent studies, the HIF2α antagonist, PT2399, decreased HIF2α-dependent transcription and tumor growth in selected VHL-deficient clear-cell renal cell carcinoma (ccRCC) models. These studies validate HIF2α as a therapeutic target in ccRCC, reveal variable sensitivity to HIF2α antagonism, and provide the foundation for predictive biomarker-driven clinical trials.
在两项最近的研究中，HIF2α 拮抗剂 PT2399 降低了选定的 VHL 缺陷型透明细胞肾细胞癌（ccRCC）模型中 HIF2α 依赖性转录和肿瘤生长。这些研究验证了 HIF2α 作为 ccRCC 的治疗靶点，揭示了对 HIF2α 拮抗作用的可变敏感性，并为预测生物标志物驱动的临床试验提供了基础。
